Series supported by Intellia Therapeutics
Intellia’s Modular CRISPR/Cas9 Gene Editing Platform for the Treatment of Disease
Laura Sepp-Lorenzino, Ph.D., Executive Vice President, Chief Scientific Officer, Intellia Therapeutics
About Laura Sepp-Lorenzino
Safety considerations in therapeutic genome editing
Toni Cathomen, University of Freiburg
About Toni Cathomen
Repurposing of bacterial CRISPR-Cas immunity for genome editing
Virgis Siksnys, Vilnius University, Institute of Biotechnology
Video available to ESGCT members only
About Virgis Siksnys